73 related articles for article (PubMed ID: 35138919)
1. Phase II Study of Taselisib in
Krop IE; Jegede OA; Grilley-Olson JE; Lauring JD; Mitchell EP; Zwiebel JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Kono SA; Ford JM; Garcia AA; Sui XD; Siegel RD; Slomovitz BM; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2022 Feb; 6():e2100424. PubMed ID: 35138919
[TBL] [Abstract][Full Text] [Related]
2. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
Lopez S; Schwab CL; Cocco E; Bellone S; Bonazzoli E; English DP; Schwartz PE; Rutherford T; Angioli R; Santin AD
Gynecol Oncol; 2014 Nov; 135(2):312-7. PubMed ID: 25172762
[TBL] [Abstract][Full Text] [Related]
3. Phase II Study of Erdafitinib in Patients With Tumors With
Gong J; Mita AC; Wei Z; Cheng HH; Mitchell EP; Wright JJ; Ivy SP; Wang V; Gray RC; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Alva AS; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2024 Apr; 8():e2300406. PubMed ID: 38603651
[TBL] [Abstract][Full Text] [Related]
4. Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.
Kalinsky K; Hong F; McCourt CK; Sachdev JC; Mitchell EP; Zwiebel JA; Doyle LA; McShane LM; Li S; Gray RJ; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Conley BA; O'Dwyer PJ; Harris LN; Arteaga CL; Chen AP; Flaherty KT
JAMA Oncol; 2021 Feb; 7(2):271-278. PubMed ID: 33377972
[TBL] [Abstract][Full Text] [Related]
5. Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.
Gong J; Mita AC; Wei Z; Cheng HH; Mitchell EP; Wright JJ; Ivy SP; Wang V; Gray RC; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2024 Apr; 8():e2300407. PubMed ID: 38603650
[TBL] [Abstract][Full Text] [Related]
6. Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer.
Grinshpun A; Ren S; Graham N; DeMeo MK; Wrabel E; Carter J; Tayob N; Pereslete A; Hamilton E; Juric D; Mayer EL; Tolaney SM; Krop IE; Metzger O
ESMO Open; 2024 Jun; 9(6):103465. PubMed ID: 38833970
[TBL] [Abstract][Full Text] [Related]
7. Trametinib in Patients With
Wisinski KB; Flamand Y; Wilson MA; Luke JJ; Tawbi HA; Hong F; Mitchell EP; Zwiebel JA; Chen H; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Behrens RJ; Pennington KP; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2023 Apr; 7():e2200421. PubMed ID: 37053535
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
Connolly RM; Wang V; Hyman DM; Grivas P; Mitchell EP; Wright JJ; Sharon E; Gray RJ; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Wang J; Wisinski KB; Tricoli JV; Conley BA; Harris LN; Arteaga CL; O'Dwyer PJ; Chen AP; Flaherty KT
Clin Cancer Res; 2024 Apr; 30(7):1273-1280. PubMed ID: 38433347
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and prognosis of PIK3CA mutations in Bulgarian patients with metastatic breast cancer receiving endocrine therapy in first-line setting.
Gencheva R; Petrova M; Kraleva P; Hadjidekova S; Radanova M; Conev N; Stoyanov D; Arabadjiev J; Tazimova E; Bachurska S; Eneva M; Tsvetkova M; Zhbantov G; Karanikolova T; Manov D; Ivanova A; Taushanova-Hadjieva M; Staneva R; Dimitrova E; Donev I
Cancer Rep (Hoboken); 2023 Dec; 7(2):e1966. PubMed ID: 38148576
[TBL] [Abstract][Full Text] [Related]
10. National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH).
Meric-Bernstam F; Ford JM; O'Dwyer PJ; Shapiro GI; McShane LM; Freidlin B; O'Cearbhaill RE; George S; Glade-Bender J; Lyman GH; Tricoli JV; Patton D; Hamilton SR; Gray RJ; Hawkins DS; Ramineni B; Flaherty KT; Grivas P; Yap TA; Berlin J; Doroshow JH; Harris LN; Moscow JA
Clin Cancer Res; 2023 Apr; 29(8):1412-1422. PubMed ID: 36662819
[TBL] [Abstract][Full Text] [Related]
11. Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
Varkaris A; Pazolli E; Gunaydin H; Wang Q; Pierce L; Boezio AA; Bulku A; DiPietro L; Fridrich C; Frost A; Giordanetto F; Hamilton EP; Harris K; Holliday M; Hunter TL; Iskandar A; Ji Y; Larivée A; LaRochelle JR; Lescarbeau A; Llambi F; Lormil B; Mader MM; Mar BG; Martin I; McLean TH; Michelsen K; Pechersky Y; Puente-Poushnejad E; Raynor K; Rogala D; Samadani R; Schram AM; Shortsleeves K; Swaminathan S; Tajmir S; Tan G; Tang Y; Valverde R; Wehrenberg B; Wilbur J; Williams BR; Zeng H; Zhang H; Walters WP; Wolf BB; Shaw DE; Bergstrom DA; Watters J; Fraser JS; Fortin PD; Kipp DR
Cancer Discov; 2024 Feb; 14(2):240-257. PubMed ID: 37916956
[TBL] [Abstract][Full Text] [Related]
12. Signature program: a platform of basket trials.
Slosberg ED; Kang BP; Peguero J; Taylor M; Bauer TM; Berry DA; Braiteh F; Spira A; Meric-Bernstam F; Stein S; Piha-Paul SA; Salvado A
Oncotarget; 2018 Apr; 9(30):21383-21395. PubMed ID: 29765547
[TBL] [Abstract][Full Text] [Related]
13. Anticancer potential of grifolin in lung cancer treatment through PI3K/AKT pathway inhibition.
Wang L; Wang Y; Wang Z; Zhang X; Chen H; Lin Q; Wang X; Wen Y; Pan X; Guo Z; Wan B
Heliyon; 2024 Apr; 10(8):e29447. PubMed ID: 38644824
[TBL] [Abstract][Full Text] [Related]
14. Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution.
Aleksakhina SN; Ivantsov AO; Imyanitov EN
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612902
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity in precision oncology.
Tomasik B; Garbicz F; Braun M; Bieńkowski M; Jassem J
Camb Prism Precis Med; 2024; 2():e2. PubMed ID: 38549846
[TBL] [Abstract][Full Text] [Related]
16. PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment.
Leiphrakpam PD; Are C
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542151
[TBL] [Abstract][Full Text] [Related]
17. Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers.
Shan KS; Bonano-Rios A; Theik NWY; Hussein A; Blaya M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396649
[TBL] [Abstract][Full Text] [Related]
18. Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial.
Zhou I; Plana D; Palmer AC
Clin Cancer Res; 2024 Feb; 30(4):786-792. PubMed ID: 38109210
[TBL] [Abstract][Full Text] [Related]
19. Home-run trials for rare cancers: giving the right drug(s) to the right patients at the right time and in the right place.
Adashek JJ; Kurzrock R
NPJ Precis Oncol; 2023 Dec; 7(1):129. PubMed ID: 38066094
[TBL] [Abstract][Full Text] [Related]
20. Identifying cancer driver genes in individual tumours.
Gillman R; Field MA; Schmitz U; Karamatic R; Hebbard L
Comput Struct Biotechnol J; 2023; 21():5028-5038. PubMed ID: 37867967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
